Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eszopiclone for CPAP Adherence in COMISA
NCT06017921Phase 4Completed
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Aug 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Insomnia and obstructive sleep apnea (OSA) comparing Eszopiclone with Placebo (2 arms). Primary endpoint: Short-term CPAP adherence (use > 4 hours per night) at 4 weeks. Started Aug 2023; status: completed.
02
Drugs
eszopiclone
03
Conditions
Insomniaobstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT06017921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06017921.